AACR logo

More articles from Preclinical Development

BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, Roderich E. Schwarz

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2644-2653; DOI: 10.1158/1535-7163.MCT-12-0447
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricarda Finnern, Melanie Fuergut, Dieter Zopf, Jerry W. Slootstra, Patrick A. Baeuerle, Benno Rattel, Peter Kufer

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2664-2673; DOI: 10.1158/1535-7163.MCT-12-0042
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason, Michael R. Verneris, Deborah A. Todhunter, Bin Zhang, Valarie McCullar, Sophia X. Zhou, Angela Panoskaltsis-Mortari, Louis M. Weiner, Daniel A. Vallera, Jeffrey S. Miller

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2674-2684; DOI: 10.1158/1535-7163.MCT-12-0692
Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, David A. Proia

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2633-2643; DOI: 10.1158/1535-7163.MCT-12-0615
Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servely, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bièche, Didier Decaudin, Elisabetta Marangoni

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2693-2703; DOI: 10.1158/1535-7163.MCT-12-0441-T
Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jérôme Moreaux, Thierry Rème, Wim Leonard, Jean-Luc Veyrune, Guilhem Requirand, Hartmut Goldschmidt, Dirk Hose, Bernard Klein

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2685-2692; DOI: 10.1158/1535-7163.MCT-12-0721
Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, David S. Ziegler

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2654-2663; DOI: 10.1158/1535-7163.MCT-12-0352
A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability
Tomonori Takekoshi, Joshua J. Ziarek, Brian F. Volkman, Sam T. Hwang

Molecular Cancer Therapeutics Nov 2012, 11 (11) 2516-2525; DOI: 10.1158/1535-7163.MCT-12-0494
Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma
Devin G. Roller, Mark Axelrod, Brian J. Capaldo, Karin Jensen, Aaron Mackey, Michael J. Weber, Daniel Gioeli

Molecular Cancer Therapeutics Nov 2012, 11 (11) 2505-2515; DOI: 10.1158/1535-7163.MCT-12-0461
Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
Hee-Yeon Cho, Weijun Wang, Niyati Jhaveri, Shering Torres, Joshua Tseng, Michelle N. Leong, David Jungpa Lee, Amir Goldkorn, Tong Xu, Nicos A. Petasis, Stan G. Louie, Axel H. Schönthal, Florence M. Hofman, Thomas C. Chen

Molecular Cancer Therapeutics Nov 2012, 11 (11) 2462-2472; DOI: 10.1158/1535-7163.MCT-12-0321

Main menu

User menu

Search

More articles from Preclinical Development

Pages

Articles

Info for

About MCT